INT131: A Selective Modulator of PPARγ

Journal of Molecular Biology

Volumn 386, Issue 5, 2009, Pages 1301-1311

  Motani, Alykhan ^a   Wang, Zhulun ^a   Weiszmann, Jennifer ^a   McGee, Lawrence R ^a   Lee, Gary ^a   Liu, Qingxiang ^a   Staunton, Jocelyn ^a   Fang, Zexu ^a   Fuentes, Helen ^a   Lindstrom, Michelle ^a   Liu, Jinsong ^a   Biermann, Donna H T ^a   Jaen, Juan ^a   Walker, Nigel P C ^a   Learned, R Marc ^a   Chen, Jin Long ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

Author keywords

diabetes; INT131; peroxisome proliferator activated receptor ; T131; TZD

Indexed keywords

INT 131; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TYROSINE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; CARDIOMEGALY; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG STRUCTURE; GENE ACTIVATION; GENE TARGETING; GLUCOSE TOLERANCE; HEART WEIGHT; HEMODILUTION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; INSULIN SENSITIVITY; LIGAND BINDING; LUNG WEIGHT; MALE; MUTAGENESIS; NONHUMAN; PLASMA VOLUME; PRIORITY JOURNAL; PROADIPOCYTE; RAT; WEIGHT GAIN; X RAY CRYSTALLOGRAPHY; ZUCKER RAT;

RATTUS;

EID: 60849095073     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.01.025     Document Type: Article

References (31)

1. Rosen E.D., and Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (2001) 37731-37734
2. Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 97 (1999) 161-163
3. Evans R.M., Barish G.D., and Wang Y.X. PPARs and the complex journey to obesity. Nat. Med. 10 (2004) 355-361
4. Semple R.K., Chatterjee V.K., and O'Rahilly S. PPAR gamma and human metabolic disease. J. Clin. Invest. 116 (2006) 581-589
5. Martens F.M., Visseren F.L., Lemay J., de Koning E.J., and Rabelink T.J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62 (2002) 1463-1480
6. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004) 256-263
7. Robinson J.G. Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE. Curr. Atheroscler. Rep. 9 (2007) 64-71
8. Boden G., and Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert. Opin. Invest. Drugs 15 (2006) 243-250
9. Patel C., Wyne K.L., and McGuire D.K. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?. Diabetes Vasc. Dis. Res. 2 (2005) 61-66
10. Shearer B.G., and Billin A.N. The next generation of PPAR drugs: do we have the tools to find them?. Biochim. Biophys. Acta 1771 (2007) 1082-1093
11. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007) 2457-2471
12. Tang W.H., and Maroo A. PPARgamma agonists: safety issues in heart failure. Diabetes Obes. Metab. 9 (2007) 447-454
13. Picard F., and Auwerx J. PPAR(gamma) and glucose homeostasis. Annu. Rev. Nutr. 22 (2002) 167-197
14. Knouff C., and Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 25 (2004) 899-918
15. Florez J.C. Phenotypic consequences of the peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism: the weight of the evidence in genetic association studies. J. Clin. Endocrinol. Metab. 89 (2004) 4234-4237
16. Li Y., Wang Z., Furukawa N., Escaron P., Weiszmann J., Lee G., et al. T2384, a novel antidiabetic agent with unique PPARγ binding properties. J. Biol. Chem. 283 (2008) 9168-9176
17. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276 (2001) 41245-41254
18. Argmann C.A., Cock T.A., and Auwerx J. Peroxisome proliferator-activated receptor gamma: the more the merrier?. Eur. J. Clin. Invest. 35 (2005) 82-92 discussion 80
19. McGee L.R., Rubenstein S.M., Houze J.B., Ye G., Li Y., Learned R.M., et al. Proceedings of the 231st American Chemical Society National Meeting, Atlanta, GA, USA (2006)
20. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3 (1999) 397-403
21. Cronet P., Petersen J.F., Folmer R., Blomberg N., Sjoblom K., Karlsson U., et al. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9 (2001) 699-706
22. Oberfield J.L., Collins J.L., Holmes C.P., Goreham D.M., Cooper J.P., Cobb J.E., et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl Acad. Sci. USA 96 (1999) 6102-6106
23. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
24. Einstein M., Akiyama T.E., Castriota G.A., Wang C.F., McKeever B., Mosley R.T., et al. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities. Mol. Pharmacol. 73 (2008) 62-74
25. Lee G., Elwood F., McNally J., Weiszmann J., Lindstrom M., Amaral K., et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J. Biol. Chem. 277 (2002) 19649-19657
26. Higgins L.S., and Mantzoros C.S. The development of INT131 as a selective PPARgamma modulator: approach to a safer insulin sensitizer. PPAR Res. 2008 (2008) 936906
27. Sotiropoulos K.B., Clermont A., Yasuda Y., Rask-Madsen C., Mastumoto M., Takahashi J., et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J. 20 (2006) 1203-1205
28. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 (1999) 880-883
29. Otwinowski Z.A.M.W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
30. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. Sect. D 54 (1998) 905-921
31. Leslie A.G.W. Recent changes to the MOSFLM package for processing film and image plate data. Jt. CCP4+ESF-EAMCB Newsl. Protein Crystallogr. 26 (1992)